CN119212985A - Erk的吡咯抑制剂的氘代类似物、其合成及其中间体 - Google Patents

Erk的吡咯抑制剂的氘代类似物、其合成及其中间体 Download PDF

Info

Publication number
CN119212985A
CN119212985A CN202380038832.XA CN202380038832A CN119212985A CN 119212985 A CN119212985 A CN 119212985A CN 202380038832 A CN202380038832 A CN 202380038832A CN 119212985 A CN119212985 A CN 119212985A
Authority
CN
China
Prior art keywords
compound
formula
deuterium
pharmaceutical composition
produce
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380038832.XA
Other languages
English (en)
Chinese (zh)
Inventor
G·德克雷斯森佐
M·特里斯克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomed Valley Discoveries Inc
Original Assignee
Biomed Valley Discoveries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomed Valley Discoveries Inc filed Critical Biomed Valley Discoveries Inc
Publication of CN119212985A publication Critical patent/CN119212985A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202380038832.XA 2022-03-24 2023-03-24 Erk的吡咯抑制剂的氘代类似物、其合成及其中间体 Pending CN119212985A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263323221P 2022-03-24 2022-03-24
US63/323,221 2022-03-24
PCT/US2023/064908 WO2023183905A2 (en) 2022-03-24 2023-03-24 Deuterated analogs of pyrrole inhibitors of erk, synthesis thereof and intermediates thereto

Publications (1)

Publication Number Publication Date
CN119212985A true CN119212985A (zh) 2024-12-27

Family

ID=88102044

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380038832.XA Pending CN119212985A (zh) 2022-03-24 2023-03-24 Erk的吡咯抑制剂的氘代类似物、其合成及其中间体

Country Status (10)

Country Link
US (1) US20250026733A1 (enExample)
EP (1) EP4499623A2 (enExample)
JP (1) JP2025509969A (enExample)
CN (1) CN119212985A (enExample)
AU (1) AU2023238106A1 (enExample)
CA (1) CA3245978A1 (enExample)
IL (1) IL315702A (enExample)
MX (1) MX2024011415A (enExample)
TW (1) TW202400572A (enExample)
WO (1) WO2023183905A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025250391A1 (en) * 2024-05-28 2025-12-04 Biomed Valley Discoveries, Inc. Compositions and methods for solid forms of ulixertinib

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA84930C2 (ru) * 2004-05-14 2008-12-10 Вертекс Фармасьютикалс Инкорпорейтед Пиррольные соединения как ингибиторы протеинкиназ erk, их синтез и соответствующие промежуточные соединения
US9227969B2 (en) * 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
HK1244274A1 (zh) * 2015-01-30 2018-08-03 生物医学谷探索股份有限公司 C21h22ci2n4o2的晶型

Also Published As

Publication number Publication date
IL315702A (en) 2024-11-01
JP2025509969A (ja) 2025-04-11
CA3245978A1 (en) 2023-09-28
WO2023183905A3 (en) 2023-10-26
TW202400572A (zh) 2024-01-01
US20250026733A1 (en) 2025-01-23
WO2023183905A2 (en) 2023-09-28
EP4499623A2 (en) 2025-02-05
AU2023238106A1 (en) 2024-09-26
MX2024011415A (es) 2024-09-24

Similar Documents

Publication Publication Date Title
JP2022071072A (ja) （ｓ）－７－（１－アクリロイルピペリジン－４－イル）－２－（４－フェノキシフェニル）－４，５，６，７－テトラ－ヒドロピラゾロ［１，５－ａ］ピリミジン－３－カルボキサミドの結晶形、その調製、及びその使用
TWI762743B (zh) 磺醯胺化合物及其用途
WO2022109182A1 (en) Polyheterocyclic glp-1 r modulating compounds
JP2023030076A (ja) Ｆｘｒアゴニストの固体形態
JP5132305B2 (ja) Ｅｒｋプロテインキナーゼのインヒビターとしてのピロール化合物、それらの合成、およびそれらの中間体
CN102459270A (zh) Janus激酶3的哌啶抑制剂
KR20100050466A (ko) 섬유증 저해제로서의 치환된 ｎ-아릴 피리디논
US10150766B2 (en) P2X7 modulators
CN104507946A (zh) 氘代依鲁替尼
US11534434B2 (en) Xanomeline derivatives and methods for treating neurological disorders
AU2018208846A1 (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as magl inhibitors
WO2007146124A2 (en) Deuterated tadalafil derivatives
WO2008100886A1 (en) Preparation and use of deuterated udenafil analogues as highly selective pde5 modulators for the treatment of erectile dysfunction
WO2015153877A1 (en) Oxindole inhibitors of tyrosine kinase
CN112469473A (zh) 作为magl抑制剂的杂环螺环化合物
US20250026733A1 (en) Deuterated analogs of pyrole inhibitors of erk, synthesis thereof and intermediates thereto
KR20160111968A (ko) 치환된 n-아릴 피리디논
US11760751B2 (en) Benzo 2-azaspiro[4.4]nonane compound and use thereof
JP7607799B2 (ja) ６員芳香族ヘテロ尿素環の誘導体及びその使用
HK40118078A (zh) Erk的吡咯抑制剂的氘代类似物、其合成及其中间体
WO2007039580A1 (en) Imidazolyl-substituted benzophenone compounds
CN111630048B (zh) 脒类和胍类衍生物、其制备方法及其在医药上的应用
CN101511180A (zh) 取代的羧酸化合物的制备及应用
JP2021531331A (ja) チアジアゾール誘導体及びｇｌｓ１阻害剤としてのその使用
WO2010011868A2 (en) Pyridine sulfonamide modulators of endothelin-a-receptor

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40118078

Country of ref document: HK